Leukemia is a cancer of the blood cells. There are several broad categories of blood cells, including red blood cells (RBCs), white blood cells (WBCs), and platelets. High levels of an enzyme known to suppress the immune system may put patients diagnosed with the most common form of leukemia at the risk of early death, say researchers.
High levels of this enzyme, indoleamine 2,3 dioxygenase, or IDO, at diagnosis can also identify those who might benefit most by taking an IDO inhibitor along with their standard therapy, said the study published in the journal Scientific Reports.
Leukemia Patients May Adopt Cancer Therapies That Have Lower Side Effects
Patients with chronic lymphocytic leukemia (CLL) have very high value for medicines that deliver the longest progression-free survival (PFS).
Advertisement
‘The onset of leukemia can be acute (sudden onset) or chronic (slow onset). Leukemia can also cause symptoms in organs that have been infiltrated or affected by the cancer cells.’
Tweet it Now
"We want to help people who are not responding to treatment and are dying very soon after their diagnosis," said Ravindra Kolhe from Medical College of Georgia at Augusta University in the US.
The researchers found that increased IDO expression in the bone marrow biopsy of patients with acute myeloid leukemia, or AML, correlated with lower overall survival rates and early mortality.
![Misregulated Protein Plays a Key Role in Leukemia, Brain Cancer]( "Misregulated Protein Plays a Key Role in Leukemia, Brain Cancer")
Research provides insight into the effect of mutations of enzymes involved in the development of leukemias and brain cancer.
It also indicates that IDO expression should routinely be measured when the diagnostic bone marrow biopsy is performed, Kolhe said.
An early phase clinical study is already underway to begin to explore the IDO inhibitor's clinical potential in these patients, the researchers said.
"We wanted to look at what makes this leukemia so aggressive that initial induction chemotherapy is not working," Kolhe said.
While everyone has the IDO gene, it's the cancer cells in this scenario that activate the disabler of the immune response, he said.
Source: IANS
Misregulated Protein Plays a Key Role in Leukemia, Brain Cancer
Research provides insight into the effect of mutations of enzymes involved in the development of leukemias and brain cancer.
Advertisement
It also indicates that IDO expression should routinely be measured when the diagnostic bone marrow biopsy is performed, Kolhe said.
An early phase clinical study is already underway to begin to explore the IDO inhibitor's clinical potential in these patients, the researchers said.
"We wanted to look at what makes this leukemia so aggressive that initial induction chemotherapy is not working," Kolhe said.
While everyone has the IDO gene, it's the cancer cells in this scenario that activate the disabler of the immune response, he said.
Source: IANS
New TCR Therapy Could Help Prevent Leukemia Relapses
The TCR (T Cell Receptors) therapy could treat or prevent the relapse of leukemia better than the recent CAR (Chimeric Antigen Receptor) Therapy
Advertisement
 Bolstering of Fat Cells in Bone Marrow for Leukemia TreatmentFat cells or adipocytes in the bone marrow suppressed cancerous leukemia cells, and can be used as treatment target for leukemia. | Advertisement
|
Advertisement
Recommended Reading
Latest Research News
Decoding the eight factors affecting Black adults' life expectancy.
Sobering truth about foot travel in the United States emerges from international statistics, highlighting the prevalence of walking on the Blacksburg campus.
Unveiling a hidden mechanism, proteins within brain cells exhibit newfound abilities at synapses, reinforcing Darwin's theory of adaptation and diversity in the natural world.
Combining micro-needling and cupping, two emerging and alternative techniques, in an experimental study reveals a potential synergy for skin rejuvenation.
Despite a decline in COVID-19 cases, the World Health Organisation (WHO) raises global concerns by warning of an "inevitable" next pandemic known as "Disease X".